Weiss Ratings Reaffirms "Hold (C-)" Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C-)" rating for Agios Pharmaceuticals (NASDAQ:AGIO), indicating a cautious outlook on the stock.
• Agios Pharmaceuticals experienced a stock price increase of $0.93, reaching $43.02, with a market capitalization of $2.50 billion.
• Recent earnings revealed a loss of ($1.93) per share, missing estimates, but the company surpassed revenue expectations with $12.50 million for the quarter.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities research analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

A number of other research firms have also recently weighed in on AGIO. Scotiabank dropped their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. HC Wainwright reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, September 4th. Zacks Research cut shares of Agios Pharmaceuticals from a "hold" rating to a "strong sell" rating in a report on Monday, October 6th. Finally, Bank of America dropped their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.25.

Agios Pharmaceuticals Stock Performance

AGIO stock traded up $0.93 during trading on Friday, reaching $43.02. 133,920 shares of the company were exchanged, compared to its average volume of 696,428. The company has a market cap of $2.50 billion, a P/E ratio of 3.91 and a beta of 0.83. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The stock's 50 day moving average price is $38.89 and its 200 day moving average price is $34.99.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. As a group, equities research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Theodore James Jr. Washburn sold 8,546 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the completion of the transaction, the insider directly owned 868 shares of the company's stock, valued at approximately $32,003.16. This trade represents a 90.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian Goff sold 11,085 shares of the firm's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the sale, the chief executive officer directly owned 123,528 shares of the company's stock, valued at $4,529,771.76. This represents a 8.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,482 shares of company stock worth $864,025 in the last ninety days. Company insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of AGIO. Bellevue Group AG grew its position in Agios Pharmaceuticals by 2.1% in the second quarter. Bellevue Group AG now owns 3,590,150 shares of the biopharmaceutical company's stock valued at $119,408,000 after acquiring an additional 75,000 shares during the last quarter. Commodore Capital LP boosted its holdings in Agios Pharmaceuticals by 6.4% in the second quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company's stock valued at $77,330,000 after acquiring an additional 140,000 shares during the last quarter. Erste Asset Management GmbH boosted its holdings in Agios Pharmaceuticals by 10.9% in the first quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,405,755 shares of the biopharmaceutical company's stock worth $46,762,000 after buying an additional 11,174 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 19.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company's stock worth $42,565,000 after buying an additional 209,900 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.